With our transition into Phase 1, we look forward to sharing the results of our preclinical studies in coming publications. Stay tuned for updates as we continue to advance our research.
Tomasini, S et al., (2025). The Role of microRNA-22 in Metabolism. Int. J. Mol. Sci., 25, 26 (2), 782.
Panella, R et al., (2023). MircoRNA-22 is a Key Regulator of Lipid and Metabolic Homeostasis. Int. J. Mol. Sci., 24, 12870.
Panella, R et al., (2023). Assessment of immunostimulatory responses to the antimiR-22 oligonucleotide compound RES-010 in human peripheral blood mononuclear cells. Front. Pharmacol. Vol. 14.
Panella, R et al., (2023). Targeting of microRNA-22 Suppresses Tumor Spread in a Mouse Model of Triple-Negative Breast Cancer. Biomedicines 11(5):1470.
Yang, Z et al., (2021). MiR‐22 modulates the expression of lipogenesis‐related genes and promotes hepatic steatosis in vitro. FEBS Open Bio, 11(1), 322-332.
Lou, P et al., (2021). MiR-22 modulates brown adipocyte thermogenesis by synergistically activating the glycolytic and mTORC1 signaling pathways. Theranostics, 11(8), 3607.
Thibonnier, M et al., (2020). Metabolic and energetic benefits of microRNA-22 inhibition. BMJ Open Diabetes Research and Care, 8(1), e001478.
Hu, Y et al., (2020). miR-22 inhibition reduces hepatic steatosis via FGF21 and FGFR1 induction. JHep Reports, 2(2), 100093.
Diniz, G. P et al., (2017). Loss of microRNA-22 prevents high-fat diet induced dyslipidemia and increases energy expenditure without affecting cardiac hypertrophy. Clinical Science, 131(24), 2885-2900.
Kaur, K et al., (2015). Elevated hepatic miR-22-3p expression impairs gluconeogenesis by silencing the Wnt-responsive transcription factor Tcf7. Diabetes, 64(11), 3659-3669.
